Abstract:Stroke is the second highest disease causing burden on the global economy and one of the leading causes of non-traumatic disability [ [1] Murray C.J. Lopez A.D. Measuring the global burden of disease[J]. N Engl J Med. 2013; 369: 448-457https://doi.org/10.1056/NEJMra1201534 Crossref PubMed Scopus (1151) Google Scholar ]. As many as 30–40% of ischemic stroke cases have no identified medical cause, known as cryptogenic stroke (CS) [ [2] Hart R.G. Diener H.C. Coutts S.B. et al. Embolic strokes of undetermined source: the case for a new clinical construct[J]. Lancet Neurol. 2014; 13: 429-438https://doi.org/10.1016/S1474-4422(13)70310-7 Abstract Full Text Full Text PDF PubMed Scopus (916) Google Scholar ]. Within the last century, the incidence of patent foramen ovale (PFO) in patients with CS is as high as 50–60%, which is significantly higher than 20–30% in the normal population [ [3] Hara H. Virmani R. Ladich E. et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status[J]. J Am Coll Cardiol. 2005; 46: 1768-1776https://doi.org/10.1016/j.jacc.2005.08.038 Crossref PubMed Scopus (230) Google Scholar ]. In the past two decades, to explore the effective treatment of patients with CS and PFO, several related experiments have been conducted in the academic community. After contradictory views and negative results, it was finally confirmed that closure therapy can significantly reduce the risk of stroke recurrence [ 4 Mas J.L. Derumeaux G. Guillon B. et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med. 2017; 377: 1011-1021https://doi.org/10.1056/NEJMoa1705915 Crossref PubMed Scopus (565) Google Scholar , 5 Saver J.L. Carroll J.D. Thaler D.E. et al. Long-Term outcomes of patent foramen ovale closure or medical therapy after stroke[j]. N Engl J Med. 2017; 377: 1022-1032https://doi.org/10.1056/NEJMoa1610057 Crossref PubMed Scopus (531) Google Scholar , 6 Søndergaard L. Kasner S.E. Rhodes J.F. et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[j]. New England Journal of Medicine. 2017; 377: 1033-1042https://doi.org/10.1056/NEJMoa1707404 Crossref PubMed Scopus (554) Google Scholar ]. However, literature on the Asian population with a high incidence of stroke, particularly on biomarkers for risk factors for stroke recurrence, is currently lacking.

Patent Foramen Ovale and Stroke–Current Status

Patent Foramen Ovale and Other Cardiopathies as Causes of Embolic Stroke With Unknown Source

Patent Foramen Ovale Closure for Nonstroke Indications

Updates on Patent Foramen Ovale (PFO) Closure

Patent Foramen Ovale Closure for Patients with Cryptogenic Stroke: A Systematic Review and Comprehensive Meta‐analysis of 5 Randomized Controlled Trials and 14 Observational Studies

Transcatheter PFO closure for cryptogenic stroke: current approaches and future considerations

Patent Foramen Ovale-Associated Stroke: A Neurologist's Perspective

Patent Foramen Ovale: The Unresolved Questions

Abstract TP249: A Real World Study of PFO Closure in Young Patients With Ischemic Stroke

Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?

Comparison of Stroke Recurrence Between Antiplatelet and Closure Therapy in Cryptogenic Stroke Patients with Patent Foramen Ovale and Its Influencing Factors

[Patent foramen ovale and stroke]

Patent foramen ovale and stroke in childhood: A systematic review of the literature

Arrhythmias Following Patent Foramen Ovale Closure: An Unsolved Enigma

Patent Foramen Ovale in Children: A Review of Recent Progress

Current status of transcatheter closure of patent foramen ovale

Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke

Insights from a 23-Year Monocentric Analysis

Assessment of the Characteristics of Patent Foramen Ovale Associated with Cryptogenic Stroke

Patent Foramen Ovale and Atrial Septal Defect

Practical Aspects of Patent Foramen Ovale Closure: Ultrasound and Fluoroscopic Guidance